Home » GSK GAINS EXPANDED INDICATION FOR BEXXAR
GSK GAINS EXPANDED INDICATION FOR BEXXAR
GlaxoSmithKline (GSK) has received FDA approval to expand the use of its cancer drug Bexxar to patients with non-Hodgkin's lymphoma (NHL).
The FDA-approved supplemental biologics license application allows GSK to market Bexxar (tositumomab and iodine I 131 tositumomab) for treatment of patients with CD 20 antigen expressing relapsed or refractory, low-grade, follicular, or transformed NHL, including patients with rituximab-refractory NHL.
The drug's original indication specified that patients must be refractory to rituximab and have relapsed following chemotherapy.
KEYWORDS Drug Pipeline Alert
Upcoming Events
-
23May
-
30May
-
13Jun
-
20Jun
-
21Oct